Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about dementia research projects that are funded by European programmes including FP7, H2020, IMI, JPND, AAL and the third EU Health programme. The mapping exercise and database were expanded in 2025, to include projects funded under Horizon Europe (including IHI). For these projects, the database reports the maximum contribution from the European Commission rather than the total project budget, so funding figures may not be directly comparable across all entries.
For an overview of projects, Alzheimer Europe is involved in, visit: https://www.alzheimer-europe.org/our-work/current-work

Filters

(Clear all)

Self-management interventions and mutual assistance community services, helping patients with dementia and caregivers connect with others for evaluation, support and inspiration to improve the care experience

CAREGIVERSPRO-MMD

According to the World Health Organisation (WHO, ADI), 44 million people around the world have some form of dementia, for which there is no effective intervention, to halt or reverse the progressive cognitive impairment. As Europe’s population is ageing, long-term care for elderly citizens will become an increasing cost for society. To manage this...

Funding Programme
EU-H2020
Start Date
End Date
Total Funding
€ 4 087 199
European Countries Involved

Smart HOme for the elderly PEople

HOPE

The Hope” solution consists of an integrated, smart platform that enables the elderly people with Alzheimer’s disease to use innovative technology for a more independent life, easy access to information, monitor their health, which provides a basis for integrating services for the elderly population while they are at home.  HOPE is a self-operated...

Funding Programme
AAL
Start Date
End Date
Total Funding
€ 2 138 094
European Countries Involved

Stratification, Management, and Guidance of Hypertrophic Cardiomyopathy Patients using Hybrid Digital Twin Solutions

SMASH-HCM

Hypertrophic cardiomyopathy (HCM) is the most common inherited heart disease (prevalence 1:200 - 1:500), manifested by thickening of cardiac walls, increasing risks of arrhythmia, and sudden cardiac death. HCM affects all ages - it is the leading cause of death among young athletes. Comorbidities due to gene mutations include altered vascular...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 8 546 366
European Countries Involved

Supple Graphene Bio-Platform for point-of-care early detection and monitoring of Alzheimer’s Disease

2D-BioPAD

2D-BioPAD is a cost-effective, non-invasive point of care/self-testing tool for the early and accurate prognosis (assistive diagnosis) of Alzheimer's Disease, with special focus on earlier stages such as Subjective or Mild Cognitive Impairment (SCI/MCI).

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 5 957 949
European Countries Involved

Targeting Circadian Clock Dysfunction in Alzheimer’s Disease

TClock4AD

Recent Nobel Prize-winning discoveries on circadian clock (CC) have laid the foundation for ground-breaking approaches to treat many diseases, including Alzheimer’s disease (AD). AD is a current public health priority. Amplifying the demographic burden of the rising numbers of patients is the low success rate of AD therapies. Given that CC genes...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 3 811 636

Transferring autonomous and non autonomous cell degeneration 3D models between EU and USA for development of effective therapies for neurodegenerative diseases (ND)

CROSS-NEUROD

Neurodegenerative diseases (NDs), such as Dementia, Parkinson’s and motor neuron diseases, are a major and continuously growing worldwide health issue, particularly devastating for patients and their families. Yet, no cures are available, largely due to the lack of knowledge of ND pathogenic mechanisms. Strikingly, co-occurrence of several NDs in...

Funding Programme
EU-H2020
Start Date
End Date
Total Funding
€ 693 000
European Countries Involved

Twinning for Excellence in Research, Training and Innovation in Protein Misfolding Diseases

Twin4Promis

Protein misfolding diseases (PMDs) are a large group of human disorders caused by protein misfolding and include serious conditions with high socio-economic impact, such as Alzheimer’s disease, systemic amyloidosis, obesity, cystic fibrosis, retinitis pigmentosa and type 2 diabetes. The vast majority of them remain incurable so there is currently a...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 1 201 375
European Countries Involved

VELES Excellence Hub - Strengthening the South-East Europe Smart Health Regional Excellence and Boosting the Innovation Potential

VELES

Smart Health is EU Strategic Value Chain that contributes to growth, jobs and competitiveness. Health Data is the main enabler for the value chain, but it also depends on cutting edge technologies - AI, cloud computing, IoT, to integrate the dispersed knowledge and support innovative healthcare solutions and services. EC sets the creation of a...

Funding Programme
EU-Horizon Europe
Start Date
End Date
Total Funding
€ 4 750 000
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).